Bulletin of the Korean Chemical Society

Korean Chemical Society (대한화학회)
권호 표지
DOI QR코드

DOI QR Code

Synthesis and Biological Evaluation of Novel GSK-3β Inhibitors as Anticancer Agents

  • Choi, Min-Jeong (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology) ;
  • Oh, Da-Won (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology) ;
  • Jang, Jae-Wan (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology) ;
  • Cho, Yong-Seo (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology) ;
  • Seo, Seon-Hee (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology) ;
  • Jeong, Kyu-Sung (Department of Chemistry, College of Science, Yonsei University) ;
  • Ko, Soo-Young (Department of Chemistry & Nano Science, Ewha Womans University) ;
  • Pae, Ae-Nim (Neuro-Medicine Center, Brain Science Institute, Korea Institute of Science and Technology)
  • Received : 2011.03.08
  • Accepted : 2011.04.19
  • Published : 2011.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

A series of isoxazol-indolin-2-one was designed for GSK-3${\beta}$ inhibitors as novel anticancer agents based on their binding mode analysis in GSK-3${\beta}$ crystal structure. Total 21 compounds were synthesized and evaluated for their inhibitory activity against two tumor cell lines (DU145 and HT29). Most of the synthesized compounds were potent with above 80% inhibitory activity at 100 ${\mu}M$, and several compounds were examined for inhibitory activity against GSK-3${\beta}$. Among them, 15(Z) ($R_1$=H, $R_2$=3-Cl-phenyl) was most active with 78% inhibition of tumor cell line (HT29) at 20 ${\mu}M$ and 72% inhibition of GSK-3${\beta}$ at 20 ${\mu}M$.

Keywords

References

  1. Meijer, L.; Flajolet, M.; Greengard, P. Trends Pharmacol. Sci. 2004, 25, 471. https://doi.org/10.1016/j.tips.2004.07.006
  2. Phiel, C. J.; Wilson, C. A.; Lee, V. M.-Y.; Klein, P. S. Nature 2003, 423, 435. https://doi.org/10.1038/nature01640
  3. Sato, N.; Meijer, L.; Skaltsounis, L.; Greengard, P.; Brivanlou, A. H. Nat. Med. 2004, 10, 55. https://doi.org/10.1038/nm979
  4. Thiel, A.; Heinonen, M.; Rintahaka, J.; Hallikainen, T.; Hemmes, A.; Dixon, D. A.; Haglund, C.; Ristimaki, A. J. Biol. Chem. 2006, 281, 4564. https://doi.org/10.1074/jbc.M512722200
  5. Michal, M.; Yoshiaki, K.; Hanneng, Z.; Jonathan, W.; Robert, M. K. Oncogene 2004, 23, 7882. https://doi.org/10.1038/sj.onc.1208068
  6. Ougolkov, A. V.; Fernandez-Zapico, M. E.; Bilim, V. N.; Smyrk, T. C.; Chari, S. T.; Billadeau, D. D. Clin. Cancer Res. 2006, 12, 5074. https://doi.org/10.1158/1078-0432.CCR-06-0196
  7. Ougolkov, A. V.; Fernandez-Zapico, M. E.; Savoy, D. N.; Urrutia, R. A.; Billadeau, D. D. Cancer Res. 2005, 65, 2076. https://doi.org/10.1158/0008-5472.CAN-04-3642
  8. Liao, X.; Zhang, L.; Thrasher, J. B.; Du, J.; Li, B. Mol. Cancer Ther. 2003, 2, 1215.
  9. Ghosh, J. C.; Altieri, D. C. Clin. Cancer Res. 2005, 11, 4580. https://doi.org/10.1158/1078-0432.CCR-04-2624
  10. Kim, H. J.; Choo, H.; Cho, Y. S.; No, K. T.; Pae, A. N. Bioorg. Med. Chem. 2008, 16, 636. https://doi.org/10.1016/j.bmc.2007.10.047

Cited by

  1. ChemInform Abstract: Synthesis and Biological Evaluation of Novel GSK-3β Inhibitors as Anticancer Agents. vol.42, pp.42, 2011, https://doi.org/10.1002/chin.201142209
  2. Recent advances in isoxazole chemistry vol.84, pp.4, 2015, https://doi.org/10.1070/RCR4503